Drugs used in the bedaquiline-based and bedaquiline–delamanid combination regimen and the proportion of patients who received them
| Drugs | Patients receiving bedaquiline-based regimen | Patients receiving bedaquiline–delamanid combination regimen | p-value |
| Subjects n | 82 | 40 | |
| Kanamycin | 16 (19.5) | 8 (20) | 0.95 |
| Terizidone | 75 (91.5) | 33 (82.5) | 0.15 |
| Pyrazinamide | 80 (97.6) | 37 (92.5) | 0.19 |
| Para-aminosalicylic acid | 75 (91.5) | 31 (77.5) | 0.03 |
| Meropenem | 0 (0) | 5 (12.5) | N/A |
| Any fluoroquinilone | 81 (98.8) | 37 (92.5) | 0.07 |
| Moxifloxacin | 26 (31.7) | 16 (40) | 0.37 |
| Levofloxacin | 81 (98.8) | 33 (82.5) | 0.001 |
| Linezolid | 67 (81.7) | 36 (90) | 0.24 |
| High-dose isoniazid | 34 (41.5) | 20 (50) | 0.37 |
| Ethionamide | 27 (32.9) | 13 (32.5) | 0.96 |
| Ethambutol | 38 (46.3) | 14 (35) | 0.23 |
| Clofazimine | 78 (95.1) | 35 (87.5) | 0.13 |
| Capreomycin | 7 (8.5) | 3 (7.5) | 0.85 |
| Bedaquiline | 82 (100) | 40 (100) | N/A |
| Delamanid | 0 (0) | 40 (100) | N/A |
Data are presented as n (%), unless otherwise stated. N/A: not applicable.